22nd Century Group receives "sell" rating from StockNews.com with Q3 loss, negative net margin, and negative return on equity.

22nd Century Group (NASDAQ: XXII), a biotechnology firm focused on tobacco products, has received a "sell" rating from StockNews.com. The company reported a Q3 loss of $0.36 per share, with a negative net margin of 275.12% and a return on equity of -380.39%. Its stock opened at $0.34, with a market cap of $3.17 million. Anson Funds Management LP increased its stake by 106.9% in Q1, while short interest declined by 38% in August.